Category: 3. Business

SAN FRANCISCO (AP) — Meta has prevailed over an existential challenge to its business that could have forced the tech giant to spin off Instagram and WhatsApp after a judge ruled that the company does not hold a monopoly in social networking.

U.S. District Judge James Boasberg issued his ruling Tuesday after the historic antitrust trial wrapped up in late May. His decision follows two separate rulings that branded Google an illegal monopoly in both search and online advertising, dealing yet another regulatory blow to the tech industry that for years enjoyed nearly unbridled growth.

READ MORE: Mark Zuckerberg takes the stand in historic antitrust trial that could force breakup of Meta

The FTC “continues to insist that Meta competes with the same old rivals it has for the last decade, that the company holds a monopoly among that small set, and that it maintained that monopoly through anticompetitive acquisitions,” Boasberg wrote in his ruling. “Whether or not Meta enjoyed monopoly power in the past, though, the agency must show that it continues to hold such power now. The Court’s verdict today determines that the FTC has not done so.”

Samsung Recognized for Commitment to Employee Growth, Well-being, and Innovation

 

Samsung Electronics Co., Ltd. is proud to announce it’s been recognized as Canada’s Top 100 Employers for 2026, by Mediacorp Canada Inc. This recognition underscores Samsung’s dedication to fostering a forward-thinking workplace that prioritizes the growth, well-being, and success of its employees.

 

“We are incredibly proud of this recognition, which is a true testament to the dedication and hard work of our team,” said Brian Shin, Samsung Electronics Canada Inc., President & CEO. “We are committed to building a resilient and forward-looking organization that empowers our employees to thrive both professionally and personally.”

 

Samsung has strengthened it focus on talent investments, ensuring employees receive the support and skills necessary to drive innovation and success in the years ahead. From comprehensive health and wellness programs to training and development opportunities, Samsung continues to strive towards high engagement and satisfaction.

Pecans, America’s only native major nut, have a storied history in the United States. Today, American trees produce hundreds of million of pounds of pecans – 80% of the world’s pecan crop. Most of that crop stays here. Pecans are used to produce pecan milk, butter and oil, but many of the nuts end up in pecan pies.

Throughout history, pecans have been overlooked, poached, cultivated and improved. As they have spread throughout the United States, they have been eaten raw and in recipes. Pecans have grown more popular over the decades, and you will probably encounter them in some form this holiday season.

I’m an extension specialist in Oklahoma, a state consistently ranked fifth in pecan production, behind Georgia, New Mexico, Arizona and Texas. I’ll admit that I am not a fan of the taste of pecans, which leaves more for the squirrels, crows and enthusiastic pecan lovers.

The spread of pecans

The pecan is a nut related to the hickory. Actually, though we call them nuts, pecans are actually a type of fruit called a drupe. Drupes have pits, like the peach and cherry.

The pecan nuts that look like little brown footballs are actually the seed that starts inside the pecan fruit – until the fruit ripens and splits open to release the pecan. They are usually the size of your thumb, and you may need a nutcracker to open them. You can eat them raw or as part of a cooked dish.

The pecan derives its name from the Algonquin “pakani,” which means “a nut too hard to crack by hand.” Rich in fat and easy to transport, pecans traveled with Native Americans throughout what is now the southern United States. They were used for food, medicine and trade as early as 8,000 years ago.

Pecans are native to the southern United States, and while they had previously spread along travel and trade routes, the first documented purposeful planting of a pecan tree was in New York in 1722. Three years later, George Washington’s estate, Mount Vernon, had some planted pecans. Washington loved pecans, and Revolutionary War soldiers said he was constantly eating them.

Meanwhile, no one needed to plant pecans in the South, since they naturally grew along riverbanks and in groves. Pecan trees are alternate bearing: They will have a very large crop one year, followed by one or two very small crops. But because they naturally produced a harvest with no input from farmers, people did not need to actively cultivate them. Locals would harvest nuts for themselves but otherwise ignored the self-sufficient trees.

It wasn’t until the late 1800s that people in the pecan’s native range realized the pecan’s potential worth for income and trade. Harvesting pecans became competitive, and young boys would climb onto precarious tree branches. One girl was lifted by a hot air balloon so she could beat on the upper branches of trees and let them fall to collectors below. Pecan poaching was a problem in natural groves on private property.

Pecan cultivation begins

Even with so obvious a demand, cultivated orchards in the South were still rare into the 1900s. Pecan trees don’t produce nuts for several years after planting, so their future quality is unknown.

To guarantee quality nuts, farmers began using a technique called grafting; they’d join branches from quality trees to another pecan tree’s trunk. The first attempt at grafting pecans was in 1822, but the attempts weren’t very successful.

Grafting pecans became popular after an enslaved man named Antoine who lived on a Louisiana plantation successfully produced large pecans with tender shells by grafting, around 1846. His pecans became the first widely available improved pecan variety.

The variety was named Centennial because it was introduced to the public 30 years later at the Philadelphia Centennial Expedition in 1876, alongside the telephone, Heinz ketchup and the right arm of the Statue of Liberty.

This technique also sped up the production process. To keep pecan quality up and produce consistent annual harvests, today’s pecan growers shake the trees while the nuts are still growing, until about half of the pecans fall off. This reduces the number of nuts so that the tree can put more energy into fewer pecans, which leads to better quality. Shaking also evens out the yield, so that the alternate-bearing characteristic doesn’t create a boom-bust cycle.

US pecan consumption

The French brought praline dessert with them when they immigrated to Louisiana in the early 1700s. A praline is a flat, creamy candy made with nuts, sugar, butter and cream. Their original recipe used almonds, but at the time, the only nut available in America was the pecan, so pecan pralines were born.

During the Civil War and world wars, Americans consumed pecans in large quantities because they were a protein-packed alternative when meat was expensive and scarce. One ounce of pecans has the same amount of protein as 2 ounces of meat.

After the wars, pecan demand declined, resulting in millions of excess pounds at harvest. One effort to increase demand was a national pecan recipe contest in 1924. Over 21,000 submissions came from over 5,000 cooks, with 800 of them published in a book.

Pecan consumption went up with the inclusion of pecans in commercially prepared foods and the start of the mail-order industry in the 1870s, as pecans can be shipped and stored at room temperature. That characteristic also put them on some Apollo missions. Small amounts of pecans contain many vitamins and minerals. They became commonplace in cereals, which touted their health benefits.

In 1938, the federal government published the pamphlet Nuts and How to Use Them, which touted pecans’ nutritional value and came with recipes. Food writers suggested using pecans as shortening because they are composed mostly of fat.

The government even put a price ceiling on pecans to encourage consumption, but consumers weren’t buying them. The government ended up buying the surplus pecans and integrating them into the National School Lunch Program.

While you are sitting around the Thanksgiving table this year, you can discuss one of the biggest controversies in the pecan industry: Are they PEE-cans or puh-KAHNS?

Housing bosses at a Surrey council have said they need another £107,000 and more staff to fix deep-rooted problems in the service.

In September, the Regulator of Social Housing (RSH) gave Tandridge District Council a rating of C4 – meaning there were very serious failings and potential for government intervention.

Of the extra money, £87,000 would be spent on salaries for extra staff to help the department and £20,000 on “service costs”, according to the Local Democracy Reporting Service.

Head of housing at the authority, Jane Rochelle, said: “We’re working at a tremendous pace and I’m putting my whole team under pressure.”

She added: “I don’t intend to take my foot off the gas this side of Christmas at least.”

The council had already carved out £420,000 from the housing revenue accounts operating surplus to kickstart the housing improvement plan before the inspection results came in.

The scale of the work under way was outlined at the council’s housing committee on 11 November.

Housing officers are trying to catch up with national standards right across the service, from rewriting policies to overhauling IT systems and carrying out thousands of overdue tenancy audits.

Housing leaders have said they are focusing on what the RSH calls the “big six” safety areas – things like gas, electric, fire, asbestos and water safety.

One of the main issues is a backlog of about 2,000 tenancy audits, which are basic checks that confirm who lives in each property, identify vulnerabilities and pick up risks like fuel poverty or damp.

Savills is currently inspecting every council home, according to a council report, and said of the 710 properties it had already surveyed – about 30% of the stock – most windows and doors would need replacing “sooner rather than later”.

It also said many homes would need insulation upgrades, and many boilers would require associated pipework and radiators to be replaced.

But officers found kitchens and bathrooms to be generally in a fair condition, and said the stock overall is not in a poor condition, but would be “hungry for investment” in the next decade.

The new housing boss said she was “fairly comfortable” with the results and hoped there would not be any more nasty surprises.

Tandridge’s improvement plan will continue into 2026/27 with progress reported back to both the regulator and councillors.

Visma, one of Europe’s biggest software companies, has approached a leading City grandee to become its chair if it goes ahead with a blockbuster €20bn listing in London next spring.

Sir Ron Kalifa, former boss of payments group Worldpay and a director of the Bank of England, is considered the leading candidate for the potential role after a round of interviews in recent weeks, the Guardian understands.

However, sources close to the process cautioned that London is not yet certain to land the sought-after listing of the Norwegian company, which has been backed by UK-based private equity firm Hg Capital for almost two decades.

Stockholm has emerged as a rival because Visma is better known in Scandinavian markets, and because the Swedish bourse last month hosted the successful €13.7bn flotation, or initial public offering (IPO), of security services group Verisure, whose shares rose 25% on debut.

The absence of similar-sized IPOs in recent years is seen as one risk to listing in London. An offer to Kalifa to join Visma’s board may depend on London being chosen. Current executive chair, Øystein Moan, who was Visma’s chief executive from 1997 to 2020, could yet stay in that role.

The Oslo-based company is currently running “early look” meetings with major fund managers to gauge likely demand for the shares and investors’ preference for listing venue and governance. The company is being advised by investment banks Goldman Sachs, Morgan Stanley and UBS.

London was reported in the summer to have beaten Amsterdam to attract the listing in what was seen as a coup – Visma would be the biggest London listing for years. An eleventh-hour loss to Stockholm would be regarded as a heavy blow. “There are different routes this could go down and nothing is yet decided,” said one source close to the process.

The potential recruitment of Kalifa may become important to London’s case. Kalifa was chief executive of Worldpay for more than 10 years and later vice chair. He led the group through a period of rapid growth during which it was bought out of Royal Bank of Scotland after the financial crash and later re-emerged as a standalone FTSE 100 company. Worldpay was bought by US rival Vantiv for £9.3bn in 2017.

A London listing would also represent a personal win for Kalifa. He wrote a high-profile report for government in 2021 into how to boost the UK’s financial technology sector by attracting investment and new companies – including how to encourage them to choose London.

skip past newsletter promotion

after newsletter promotion

While Visma is not a pure technology company, it sees the development of AI products to “simplify and automate complex processes” as critical to its business in the next few years.

The group makes accounting, payroll and HR software products for 2.2 million customers. It has 17,500 employees and describes itself as the leading provider outside North America of “mission-critical business software”.

–   EPKINLY plus rituximab and lenalidomide (EPKINLY + R²) is now the first and only bispecific antibody combination therapy available for patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy
–   In the Phase 3 EPCORE^® FL-1 trial, EPKINLY + R² demonstrated significantly superior progression-free survival and overall response rates compared to standard of care R² with approximately 3 out of 4 patients achieving a complete response
–   Approval marks third indication for EPKINLY and first-ever FDA approval for a bispecific combination therapy in lymphoma

NORTH CHICAGO, Ill., Nov. 18, 2025 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that EPKINLY^® (epcoritamab-bysp), a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab and lenalidomide (EPKINLY + R²) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). This approval of EPKINLY is based on results from the pivotal Phase 3 EPCORE^® FL-1 study that evaluated fixed duration EPKINLY + R² compared to standard of care R² and demonstrates the potential of this combination therapy to reshape FL treatment and to reach patients earlier in their treatment.ⁱ 

“Recurrent follicular lymphoma can be an incurable, complex and persistent disease, creating a clear need for additional treatments that can change its course earlier in the treatment journey,” said Lorenzo Falchi, M.D., lymphoma specialist, department of medicine, Memorial Sloan Kettering Cancer Center. “The results shown with EPKINLY + R² in the EPCORE FL-1 study are incredibly meaningful, demonstrating durable responses compared to patients treated with R² alone. These data, delivered by a regimen that’s chemotherapy-free and can be administered in the outpatient setting, suggest that EPKINLY + R² could potentially become a new standard of care.”

FL is typically an indolent (slow-growing) form of non-Hodgkin lymphoma (NHL) that arises from B-lymphocytes and impacts approximately 15,000 new patients per year in the U.S.^ii,iii The disease is considered incurable with current available therapies.^iv Patients with FL often relapse, and in some cases, the disease can transform into a more aggressive form of NHL called diffuse large B-cell lymphoma (DLBCL).^v

The Phase 3 EPCORE FL-1 study included a broad range of patients, including those with indolent to aggressive disease. In the study, EPKINLY + R² reduced the risk of disease progression or death by 79% (HR 0.21, 95% CI: 0.13% – 0.33%, p<0.0001) compared to standard of care R² alone. In the dual primary endpoint of overall response rate (ORR), 89% of patients treated with EPKINLY + R² responded to treatment (n=216/243, 95% CI: 84% – 93%; p<0.0001) compared to 74% of patients treated with R² (n=181/245, 95% CI: 68%-79%). The median for dual primary endpoint of progression-free survival (PFS), was not reached (NR) among patients treated with EPKINLY + R² (95% CI: 21.9 months – NR) compared to 11.2 months for patients treated with R² (95% CI: 10.5 months – NR). Among patients who were treated with EPKINLY + R², 74% achieved a complete response (CR) (n=181/243, 95% CI: 69% – 80%, p<0.0001) compared to 43% of patients treated with R² (n=106/245, 95% CI: 37% – 50%).ⁱ

The safety profile of EPKINLY + R² in the EPCORE FL-1 study was generally consistent with the known safety profiles of the individual regimens (epcoritamab and R²).  The most common (≥ 20%) adverse reactions in patients who received EPKINLY + R² were rash, upper respiratory tract infections, fatigue, injection site reactions, constipation, diarrhea, cytokine release syndrome (CRS), pneumonia, COVID-19 and fever. The most common Grade 3 to 4 laboratory abnormalities (≥ 10%) were decreased neutrophil count, lymphocyte count, and platelets. CRS occurred in 24% of patients at the recommended 3 step-up dosage schedule, and was primarily low grade (19% Grade 1, 5% Grade 2). A single event of immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in one patient, grade 1 (0.8%). The prescribing information has a Boxed Warning for serious or life-threatening CRS and ICANS. Warnings and precautions include infections, cytopenias, and embryo-fetal toxicity. Please see additional Important Safety Information below.

“Today’s milestone marks meaningful progress for people living with follicular lymphoma. With a bispecific-based therapy that can be administered in a variety of medical settings, patients have the possibility of accessing this treatment at sites of care closer to where they live,” said Meghan Gutierrez, chief executive officer, Lymphoma Research Foundation.

EPKINLY + R² was previously granted Breakthrough Therapy Designation (BTD) by the FDA for the treatment of R/R FL. This designation is an FDA process designed to expedite the development and review of drugs that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).

“With this approval, EPKINLY is now the first bispecific antibody available for patients with follicular lymphoma in the second-line plus setting. New options are needed to improve outcomes for patients with relapsed or refractory disease,” said Daejin Abidoye, MD, vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie.

In June 2024, EPKINLY monotherapy was granted accelerated approval by the FDA for the treatment of R/R FL following two or more lines of systemic therapy. With the results of the confirmatory Phase 3 EPCORE FL-1 study, the FDA has also converted this accelerated approval to a full approval. Both companies will pursue additional international regulatory approvals for the R/R FL indication.

Data from the Phase 3 EPCORE FL-1 study will be presented at the Annual Meeting and Exposition of the American Society of Hematology (ASH) in December 2025.

About the EPCORE^® FL-1 Trial 
EPCORE FL-1 (NCT05409066) is a Phase 3 open-label randomized interventional trial to evaluate the safety and efficacy of epcoritamab plus rituximab and lenalidomide (R²) versus R² alone in patients with relapsed/refractory (R/R) follicular lymphoma (FL). Patients were randomized to receive EPKINLY in combination R² (n=243) or R² alone (n=245). Patients received EPKINLY in 28-day cycles for a total of 12 cycles or until disease progression or unacceptable toxicity, whichever occurred first. Efficacy was established based on the dual primary endpoints of progression free survival (PFS) and overall response rate (ORR) determined by Lugano 2014 criteria as assessed by Independent Review Committee (IRC). Additional efficacy outcome measures include complete response (CR) and duration of response (DOR).

EPKINLY® (epcoritamab-bysp) U.S. INDICATIONS AND IMPORTANT SAFETY INFORMATION

What is EPKINLY?
EPKINLY is a prescription medicine used to treat adults with:

• certain types of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory), after 2 or more treatments.
  • EPKINLY for the treatment of DLBCL is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY.
• follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab
• follicular lymphoma (FL) that has come back or that did not respond after receiving 2 or more treatments.

It is not known if EPKINLY is safe and effective in children.

Important Warnings—EPKINLY can cause serious side effects, including:

• Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
• Neurologic problems that can be serious, and can be life-threatening, and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

People with DLBCL or high-grade B-cell lymphoma should be hospitalized for 24 hours after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems.

People with follicular lymphoma (FL) may need to be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS.

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away.

EPKINLY can cause other serious side effects, including:

• Infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, feeling weak or generally unwell, or confusion.
• Low blood cell counts, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

The most common side effects of EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma or FL include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. The most common severe abnormal laboratory test results with EPKINLY when used alone include decreased white blood cells, decreased red blood cells, and decreased platelets.

The most common side effects of EPKINLY when used together with lenalidomide and rituximab in FL include rash, upper respiratory tract infections, tiredness, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19, and fever. The most common severe abnormal laboratory test results with EPKINLY when used together with lenalidomide and rituximab include decreased white blood cells and decreased platelets.

These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see Medication Guide, including Important Warnings.

About EPKINLY^® (epcoritamab-bysp)
EPKINLY^® (epcoritamab-bysp) is an IgG1-bispecific antibody created using Genmab’s proprietary DuoBody^® technology and administered subcutaneously. Genmab’s DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.^vi 

Epcoritamab (approved under the brand name EPKINLY in countries including the U.S. and Japan, and as TEPKINLY^® in the European Union) has received regulatory approval in certain lymphoma indications in more than 65 countries. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies’ oncology collaboration. The companies will share commercialization responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the R/R FL indication and additional approvals for the R/R DLBCL indication. 

Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes four additional ongoing Phase 3, open-label, randomized trials including a trial evaluating epcoritamab as a monotherapy in patients with R/R DLBCL compared to investigators choice immunochemotherapy (NCT04628494), a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL (NCT05578976), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R²) compared to chemoimmunotherapy in patients with previously untreated FL (NCT06191744), and a trial evaluating epcoritamab in combination with lenalidomide compared to chemotherapy infusion in patients with R/R DLBCL (NCT06508658). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit www.clinicaltrials.gov for more information.

About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world’s most widespread and debilitating cancers. As we work to have a remarkable impact on people’s lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.

About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

AbbVie Forward-Looking Statements 
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Contacts:

ⁱ EPKINLY (epcoritamab-bysp) [package insert]. Copenhagen, Denmark: Genmab, 2025.
ⁱⁱ Lymphoma Research Foundation official website. https://lymphoma.org/aboutlymphoma/nhl/fl/. Accessed November 2025.
ⁱⁱⁱ Leukemia & Lymphoma Society. https://www.lls.org/research/follicular-lymphoma-fl. Accessed November 2025.
^iv Ghione P, Palomba ML, Ghesquieres H, et al. Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study. Haematologica. 2023;108(3):822-832. doi: 10.3324/haematol.2022.281421.
^v Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2008 Nov 10;26(32):5165-9. doi: 10.1200/JCO.2008.16.0283. Epub 2008 Oct 6. PMID: 18838711.
^vi Engelberts PJ, et al. DuoBody-CD3xCD20 Induces Potent T-Cell-Mediated Killing of Malignant B Cells in Preclinical Models and Provides Opportunities for Subcutaneous Dosing. EBioMedicine. 2020;52:102625. doi: 10.1016/j.ebiom.2019.102625.

 

SOURCE AbbVie

DUBAI, ABU DHABI and RIYADH, November 18, 2025: Partner Sara K. Aranjo has been recognized as a 2026 Global Elite Thought Leader in International Arbitration by Lexology. The award honors lawyers who received the most nominations and endorsements from peers, corporate counsel, and clients, noting that recipients, “are worthy of special mention owing not only to their vast expertise and experience advising on some of the world’s most significant and cutting-edge legal matters, but also their ability to innovate, inspire, and go above and beyond to deliver for their clients.”

A partner and the leader of the Morgan Lewis international arbitration practice in the Middle East and Africa, Sara focuses her practice on international arbitration and dispute prevention and resolution, primarily in cases with cross-border elements. She advises and represents the interests of governments, semi-governments, and corporations in proceedings arising out of inbound and outbound investments in the Middle East and Africa across a range of sectors, including energy, real estate, hospitality, construction, banking and finance, distribution, and technology, media, and telecommunications.

Read the entire list here.

Belem – The International Air Transport Association (IATA), together with the governments of Japan, Malaysia, and leading industry stakeholders, have issued a joint statement at COP30 (pdf), urging governments and the international community to reaffirm the International Civil Aviation Organization (ICAO)’s leadership and accelerate coordinated climate action for aviation to reach net zero carbon emissions by 2050.

Specifically, the signatories highlight the need for global solutions, emphasizing that ICAO remains the exclusive forum for addressing international aviation emissions. The signatories caution against fragmented or unilateral measures, stressing that only a unified approach can deliver effective climate results for the sector. The signatories also stress the role of robust global carbon markets in scaling up climate finance opportunities, which is high on the COP agenda and central to the Baku to Belem Roadmap.

“Aviation is a catalyst for global connectivity and economic development. To achieve net zero emissions by 2050, governments must reaffirm ICAO’s role as the single global authority, fully implement CORSIA, and operationalize Article 6 to unlock climate finance for developing nations. Fragmented taxes and levies will not cut emissions—they risk diverting funds from actual emission-reduction investments, which is a critical climate consideration, and will only weaken connectivity and harm those who depend on it most,” said Willie Walsh, IATA’s Director General.

Key points from the joint statement

 

• ICAO’s central role: The statement reaffirms ICAO’s authority, established under the United Nations Framework Convention on Climate Change (UNFCCC) and the Kyoto Protocol, as the sole body for regulating international aviation emissions. The signatories urge all States to uphold ICAO’s leadership and avoid duplicating mechanisms across international processes.
• Strengthening CORSIA: The signatories call on all governments to strengthen the implementation of the Carbon Offsetting and Reduction Scheme for International Aviation (CORSIA), approved by all 193 ICAO Member States, which is a cornerstone for achieving net zero carbon emissions by 2050. In CORSIA’s First Phase (2024-26), airlines are expected to purchase upwards of 200 million credits, generating USD 4–5 billion. This will increase steeply in the following years, given that the scheme is expected to offset nearly 2 billion credits through 2035. This climate finance will directly support high-quality, independently verified emission-reduction projects—particularly in developing countries—significantly advancing the objectives of the Paris Agreement and promoting sustainable development, technology transfer, and job creation.
• Urgent implementation of Article 6: The statement calls on all host countries to operationalize Article 6 of the Paris Agreement, issue Letters of Authorization (LoAs), and enable the release of CORSIA-Eligible Emissions Units (EEUs). These steps are essential to mobilize international climate finance and support sustainable development.
• Taxes and levies are not climate solutions: The signatories caution that taxes and levies, notably ticket taxes such as those proposed by emerging coalitions, are not effective climate instruments and risk negatively impacting investment capacity into real emission-reduction projects. Such measures can impair connectivity and harm developing economies and Small Island States disproportionately.

The signatories of the joint statement are:

• The governments of:
• Airlines for Europe (A4E)
• Arab Air Carriers Organization (AACO)
• Airports Council International (ACI)
• Airlines International Representation in Europe (AIRE)
• Latin American and Caribbean Air Transport Association (ALTA)
• African Airlines Association (AASA)
• Association of South Pacific Airlines (ASPA)
• Air Transport Action Group (ATAG)
• European Regions Airline Association (ERA)
• International Business Aviation Council (IBAC)
• International Coordinating Council of Aerospace Industries Associations (ICCAIA)
• National Airlines Council of Canada (NACC)
• World Travel & Tourism Council (WTTC)

> Read the joint statement (pdf)

 

For more information, please contact:

Corporate Communications

Tel: +41 22 770 2967

Email: corpcomms@iata.org